Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $7.41, but opened at $7.72. Bicycle Therapeutics shares last traded at $7.43, with a volume of 49,233 shares changing hands.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on BCYC shares. B. Riley dropped their price objective on Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. JMP Securities cut their price target on shares of Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating on the stock in a report on Friday, May 2nd. Barclays reduced their price objective on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Needham & Company LLC restated a "buy" rating and set a $29.00 target price on shares of Bicycle Therapeutics in a report on Friday, May 2nd. Finally, Royal Bank Of Canada reduced their price target on Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $25.00.
Check Out Our Latest Analysis on BCYC
Bicycle Therapeutics Trading Down 0.6%
The firm has a 50-day moving average of $8.19 and a two-hundred day moving average of $10.98. The firm has a market cap of $510.03 million, a price-to-earnings ratio of -2.36 and a beta of 1.46.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The business had revenue of $9.98 million during the quarter, compared to the consensus estimate of $8.67 million. Bicycle Therapeutics had a negative return on equity of 25.54% and a negative net margin of 790.07%. As a group, equities analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current year.
Institutional Trading of Bicycle Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC grew its position in Bicycle Therapeutics by 878.3% during the fourth quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after buying an additional 2,345 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Bicycle Therapeutics by 879.5% in the 1st quarter. GAMMA Investing LLC now owns 8,982 shares of the company's stock worth $76,000 after acquiring an additional 8,065 shares during the period. Exchange Traded Concepts LLC grew its holdings in shares of Bicycle Therapeutics by 90.3% during the 1st quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock worth $108,000 after purchasing an additional 6,057 shares in the last quarter. Cerity Partners LLC acquired a new stake in shares of Bicycle Therapeutics during the 1st quarter worth approximately $113,000. Finally, Portland Investment Counsel Inc. bought a new stake in shares of Bicycle Therapeutics during the first quarter valued at approximately $127,000. 86.15% of the stock is currently owned by institutional investors and hedge funds.
Bicycle Therapeutics Company Profile
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
